SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR Sa…
BOSTON — Compared with adult cancer patients, parents of children with cancer were more likely to be dissatisfied with the informed consent process for participating in clinical trials, according to a study from Dana-Farber/Children’s Hospital Canc…
BOSTON — People treated for cancer when they were children have a higher-than-average risk of gastrointestinal problems — some mild, some quite severe — in the years following treatment, according to a study to be presented at the 42nd Cong…
BOSTON — — Raising the survival rate of children with sarcoma in low-income countries will require steps to diagnose the disease sooner, train cancer pathologists, expand radiation therapy services, create multi-specialty teams to review each cas…
BOSTON — Researchers from Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a “watch and wait” strategy to d…
MILAN, ITALY – October 10, 2010 – Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared …
